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ABSTRACT
Cell differentiation and development are highly
regulated processes at the transcriptional level. One
of the main transcription factors that regulate these
processes is AP-2a, a cell-type speci®c protein
required for vertebrate development and embryo-
genesis. AP-2a also regulates apoptosis and cell-
cycle speci®c events by interacting with the
oncogene c-Myc. In searching for novel AP-2a-
interacting factors, using an af®nity chromato-
graphy approach, we have observed that onco-
protein DEK interacts with AP-2a in vitro. The
existence of an interaction between AP-2a and DEK
in cellular cultures was demonstrated by expression
of a tagged AP-2a form followed by immunodetec-
tion. By transient co-expression experiments using
a reporter for APOE promoter activity we have
found that DEK stimulates the transactivation
activity of AP-2a over APOE promoter. Finally,
electrophoretic mobility shift assays suggested that
DEK enhances the DNA-binding activity of AP-2a.
Our data suggest a novel cellular function of DEK as
a transcriptional co-activator.
INTRODUCTION
The family of AP-2 transcription factors is composed of four
members: AP-2a (1,2), AP-2b (3), AP-2g (4) and AP-2d (5).
Spatially and temporally restricted expression patterns of
these proteins (6±8) provide essential clues for embryonic
development (9,10), regulation of programmed cell death (11),
and cell growth and differentiation (12).
Recently, the relevance of protein±protein interaction on
AP-2a activity has been reported. AP-2a modulates the
function of Myc as a proliferative agent and also as apoptosis
inductor (13). Other known AP-2a-interacting proteins are the
retinoblastoma Rb protein (14,15), the Yin Yang 1 factor
(YY1) (16), and the transcription factors YB-1 (17) and Sp-1
(18).
We have recently described the presence of allelic
polymorphisms in the transcriptional regulatory region of
the APOE gene, which produce variations in promoter activity
(19). Two of these variants are associated with an increase in
risk for developing late-onset Alzheimer's disease (20,21). We
also found that the activity of the proximal APOE promoter is
upregulated by cAMP and retinoic acid, in astrocytic but not
hepatic cells (22). The cAMP effect is mediated, in part, by
interaction of factor AP-2a with two sites located in the APOE
proximal region (22). The stimulatory effect of cAMP on
APOE promoter in HepG2 cells involves AP-2a phosphoryl-
ation at Ser239 by protein kinase A (23). In this work, we
investigate the existence of potential AP-2a-interacting fac-
tors which may modulate AP-2a activity. We have identi®ed
the oncoprotein DEK as an AP-2a-binding factor; DEK was
found to enhance the effect of AP-2a on APOE promoter,
probably enhancing the DNA binding of AP-2a.
MATERIALS AND METHODS
Recombinant protein expression
For the construction of the pcDNA3hisAP-2 vector, which
expresses an N-terminal truncation of human AP-2a (deletion
of the ®rst 122 amino acids) with a poly-histidine extension at
its N-terminal end (hisAP-2), a fragment was ampli®ed by
PCR using pTrcHisBAP-2 vector (23) as template, followed
by cloning of the fragment into the pcDNA3 vector using the
XhoI and HindIII cloning sites.
For puri®cation of HisAP-2 from U-87 derived cell lines,
identical amounts of nuclear protein from 25 3 106 cells (24)
were diluted 50-fold with buffer D (0.2 M KCl, 20 mM
Tris±HCl, pH 7.6, 10% glycerol, 2 mM MgCl2 and protease
inhibitors) and loaded onto a 200 ml Ni2+ column (Invitrogen
Corporation) previously equilibrated in the same buffer. The
column was washed with 20 vol of buffer D and eluted in
200 ml fractions with buffer D containing 500 mM imidazole.
Human recombinant AP-2a (AP-2r) was prepared as
described previously (23). GST-DEK was an N-terminally
truncated human DEK form containing 80 amino acids fused
to GST kindly provided by Gerald Grosveld.
AP-2r af®nity chromatography
Nuclear extracts from rat liver were prepared as described
previously (25). The extracts were dialyzed against buffer B
(20 mM Tris±HCl pH 7.6, 10% glycerol, 2 mM MgCl2,
0.2 mM EDTA and 1 mM DTT) containing 0.2 M KCl and
then passed through 30 ml of a heparin±Sepharose column
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(Amersham Pharmacia Biotech). The 0.5 M KCl buffer B
eluted fractions were pooled, dialyzed against 0.1 M KCl
buffer C (25 mM Tris±HCl pH 7.6, 12.5 mM MgCl2, 20%
glycerol, 1 mM DTT and 0.1% NP-40) and passed through an
AP-2r±agarose column. This column was eluted with 1 M KCl
buffer C. The AP-2r af®nity column was constructed by
coupling 250 mg of agarose (CNBr-activated Sepharose 4B)
to 8 mg AP-2r (23) following the manufacturer's instructions
(Amersham Pharmacia Biotech).
Cell lines, transfections, luciferase and b-galactosidase
assays and electrophoretic mobility shift assays (EMSAs)
The cell lines U-87 MG (ATCC number: HTB-14) and HepG2
(ATCC number: HB-8065) were grown and transfected as
described (23). For the selection of stable U-87 cell line
expressing hisAP-2 protein, 106 cells were transfected with
20 mg of the pcDNA3hisAP2 vector and grown in selective
medium (geneticin 0.4 mg/ml). After 2 days cells were plated
in a limiting dilution in 24-well plates and AP-2a expression
in single colonies was analysed by western blot using the anti-
humanAP-2 antibody C-18 (Santa Cruz, CA). Luciferase and
b-galactosidase activities were measured as described
previously (23). EMSAs were carried out as reported (23).
The CXX oligonucleotide sequence used in this work was the
following: 5¢-CTGTGCCTGGGGCAGGGGGAGAACA-3¢.
Mass spectrometry
The identity of the puri®ed band was determined following the
same procedure described previously (23).
RESULTS
Identi®cation of DEK as an AP-2a interacting factor
using AP-2a-af®nity chromatography
To identify potential AP-2a-interacting proteins, we carried
out a two-step AP-2a-af®nity chromatography puri®cation
using nuclear extracts from rat liver. A 50 kDa protein band
was clearly enriched in the eluted fraction (Fig. 1). This band
was excised from a silver stained SDS±polyacrylamide gel,
subjected to in-gel tryptic cleavage and analysed by
nanospray-ion trap MS/MS mass spectrometry. From the
total mixture of tryptic peptides, three of them (EPFTIAQGK,
LLTNRPGTVSSLK and NVGQFSGFPFEK) were identi®ed
by a database search. All sequenced peptides showed a 100%
identity to the human DEK protein, a 43 kDa protein initially
discovered as a fusion partner of the CAN nucleoporin in a
speci®c subtype of acute myeloid leukaemia (26). The identity
between the sequenced peptides and the sequence of human
DEK indicates that the puri®ed protein is the DEK rat
homologue, which has still not been cloned. We then
investigated whether a physiologically relevant interaction
between AP-2a and DEK occurs in human cells.
The oncoprotein DEK interacts with AP-2a in human
cells
An N-terminal histidine-tagged AP-2a protein (hisAP-2) was
stably expressed in the astrocytoma cell line U-87. Two highly
expressing hisAP-2 U-87 clones, D7 and D10, were selected
(Fig. 2A, lanes 2 and 3). From these two cell clones, we were
only able to purify hisAP-2 from protein extracts from the D10
clone by using Ni2+ columns (Fig. 2B, lane 3), suggesting
that the form of hisAP-2 expressed by D7 contained a
Figure 1. Puri®cation of DEK by AP-2a af®nity chromatography. A rat
nuclear extract (E) was fractionated and enriched using an AP-2a af®nity
column (see Materials and Methods). The eluted fractions were pooled and
subjected to SDS±PAGE, followed by silver staining (1). The band indi-
cated by an arrow was identi®ed as the rat homologue of human DEK by
mass spectrometry.
Figure 2. Interaction of hisAP-2 with human DEK in U-87, D7 and D10
astrocytoma cell lines. (A) Analysis of the expression of hisAP-2 in the
stably transfected clones. Nuclear extracts (20 mg) from U-87, D7 and D10
were analysed by western blotting using C-18 antibody. As a positive con-
trol we used 1 mg of AP-2r. The arrow indicates the position of hisAP-2
band. (B) Puri®cation of hisAP-2 from the stably transfected cell clones.
Puri®ed fractions (30 ml) from U-87, D7 and D10 were analysed by western
blotting using the C-18 antibody. The arrow indicates position of hisAP-2.
(C) DNA-binding activity of the puri®ed fractions. EMSAs were carried out
using 5 and 15 ml of the puri®ed fractions from U-87, D7 and D10 and
CXX probe. As a positive control 0.5 and 1 mg of AP-2r were used. The
arrow indicates the position of the hisAP-2±DNA complex. (D) Co-puri®ca-
tion of DEK with AP-2a. Ten micrograms of the original nuclear extracts
and 40 mg of puri®ed fractions from U-87, D7 and D10 were analysed by
western blotting using a polyclonal antibody that recognizes the human
DEK protein (33). The arrow indicates the position of the DEK band. In
(A), (B) and (D), the molecular weight markers are indicated on the left.
1572 Nucleic Acids Research, 2003, Vol. 31, No. 5
non-functional protein due to some mutation or deletion in the
Ni2+-binding domain. Consistently, the fractions puri®ed from
protein extracts from D7 did not present any noticeable DNA
binding activity, whereas this activity was detected in the
fractions eluted from Ni2+ columns loaded with clone D10
extracts (Fig. 2C, compare lanes 6 and 7 with 8 and 9). We
therefore used the D7 clone as an internal control in
subsequent experiments. An unidenti®ed 110 kDa band co-
puri®ed with AP-2a and was recognised by the anti-AP-2
antibody (Fig. 2B, lane 3). A band of similar molecular weight
has been described by other authors using anti-AP-2a
antibodies (27,28).
We next investigated whether DEK co-puri®ed with
hisAP-2. The nuclear expression levels of DEK in the two
clones, D7 and D10, were similar to those of the original U-87
cell line (Fig. 2D, lanes 1±3). DEK was clearly detected in the
AP-2a-enriched fractions when nuclear extracts from clone
D10 where subjected to Ni2+-af®nity chromatography
(Fig. 2D, lane 6). In clear contrast, DEK was absent in the
eluates from either U-87 or clone D7 (Fig. 2D, lanes 4 and 5).
These data strongly suggest that DEK interacts with AP-2a in
cell cultures.
DEK increases transcriptional activity of AP-2a in
HepG2 cells
To investigate the physiological relevance of the DEK-AP-2a
interaction, we tested whether DEK could modulate AP-2a
transcriptional activity. We co-transfected increasing amounts
of a DEK expression vector with a constant amount of an
AP-2a expression vector and an APOE promoter-luciferase
reporter vector [from ±227 to +1 APOE promoter sequence
(22)] in the hepatoma cell line HepG2. According to
previously reported results (22,23,29), AP-2a transactivated
APOE promoter in these cells (Fig. 3). The addition of
increasing amounts of DEK enhanced AP-2a activity in a
dose-dependent manner (Fig. 3, black bars). AP-2a was
directly involved in this effect, since overexpression of DEK
alone did not have any effect on APOE promoter activity
(Fig. 3, grey bars). Taken together, these results suggested that
DEK plays a role as co-activator of the transcriptional activity
of AP-2a.
DEK enhances binding of AP-2a to DNA
We then examined whether a recombinant preparation of
GST-DEK affected the formation of AP-2a±DNA complexes
by EMSAs. As shown in Figure 4, while in vitro DNA binding
activity of small amounts of AP-2r (30 ng) was undetectable,
formation of AP-2r±DNA complexes could be observed in the
presence of GST-DEK. This effect of GST-DEK appeared to
be speci®c since GST did not enhance the DNA-binding
activity of AP-2a (Fig. 4). The stimulatory effect of GST-
DEK was dose dependent (Fig. 4), and we were unable to
observe the formation of DNA complexes with GST-DEK
alone (Fig. 4). In addition, the presence of GST-DEK did not
produce a signi®cant increase in the mobility of the AP-
2a±DNA complex. In our assay conditions we have been
unable to detect a supershift band with an anti-humanDEK
antibody (30) (data not shown) suggesting that DEK is not
present in the complex; it is also possible that DEK is not
recognised by the antibody in the presence of bound AP-2a
due to some kind of steric hindrance. Taken together, our
results suggest the existence of a physiologically relevant
interaction between the oncoprotein DEK and the transcrip-
tion factor AP-2a; DEK enhances AP-2a transcriptional
activity by a mechanism that appears to involve an
enhancement in AP-2a±DNA binding.
DISCUSSION
To the best of our knowledge, this is the ®rst report that
suggests a role for the oncogene DEK as co-activator of a
transcription factor. DEK contains a SAP (after SAF-A/B,
Acinus and PIAS) DNA-binding motif which is involved in
chromatin remodelling and transcription (31). Coincidentally,
Figure 3. Effect of DEK on the transcriptional activity of AP-2a in HepG2
cells. 300 ng of the APOE promoter luciferase vector pXP2-227 were co-
transfected with 300 ng of pcDNA3 (grey bars) or with an AP-2a expres-
sion vector (black bars) and increasing quantities of 0, 200, 400, 600 or
800 ng of the DEK expression vector combined with decreasing quantities
of pcDNA3 of 800, 600, 400, 200 and 0 ng. Luciferase activity was cor-
rected for the transfection ef®ciency taking into account the activity of
300 ng of b-galactosidase expression vector. Transfection assays were
performed in triplicate and results are representative of at least three
independent experiments; data are expressed as mean 6 SEM.
Figure 4. Effect of DEK on binding of AP-2r to DNA in vitro. CXX probe
was incubated with 10 (lanes 2±5), 30 (lanes 6±9) or 100 ng (lanes 10±13)
of AP-2r in the presence of either 20 (lanes 3, 7 and 11), 100 (lanes 4, 8
and 12) or 500 ng (lanes 5, 9 and 13) of GST-DEK. As negative controls,
CXX probe was incubated with 100 ng of AP-2r in the presence of either
20 (lane 16), 100 (lane 17) or 500 ng (lane 18) of GST, and 500 ng of GST-
DEK (lane 14) and GST (lane 19) were incubated with the probe in the
absence of AP-2r.
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several SAP family members, such as Miz1 (32), alter the
DNA binding activity of transcription factors, modifying their
transcriptional activity. Since DEK is known to bind con-
densed chromosomes (33) and chromatin (30,34), altering the
nucleosomal DNA topology and reducing the chromatin
replication ef®ciency (35), it is possible that DEK produces
a change in chromatin conformation that increases the DNA
binding of AP-2a. The AP-2a binding site on APOE promoter
(TGGGGCAGGG) is very similar to the known DEK binding
site in the HIV-2 promoter, which is a pets sequence
(TTGGTCAGGG) (30). Although DEK does not appear to
bind to the CXX probe in vitro, it is possible that, upon a
possible in vivo binding to DNA, DEK may act as a
recruitment factor for AP-2a. In Saccharomyces cerevisiae,
the expression of Pho5 is controlled by a similar `cooperativ-
ity' mechanism. In this case, the Pho4 transcriptional activator
is cooperatively recruited to the active sites by the homeo-
protein Pho2, a protein that binds very weakly to DNA in the
absence of Pho4 (36).
However, DEK appears to enhance the interaction of AP-2a
with DNA without affecting the rate of migration of this
complex, and no evidence was found suggesting a direct
interaction of DEK with DNA. Thus, DEK behaves similarly
to Miz1, another SAP protein, which enhances DNA binding
of the transcription factor Msx2 without forming ternary
complexes (32). Our results suggest the existence of a
transient interaction in which DEK affects the conformation
of AP-2a, enhancing its DNA binding. A similar `hit and run'
mechanism has been demonstrated for the effect of Phox 1
over DNA binding of the serum response factor (SRF); Phox 1
was proposed to lower an activation energy barrier, enhancing
the rate of stable SRF±DNA complex formation (37).
The interaction of AP-2a with DEK was demonstrated
using an N-terminally truncated AP-2a fragment. This
suggests that the interaction domain of AP-2a is located in
the C-terminal moiety, which includes the DNA binding and
dimerization domains. Both domains are highly conserved
between all members of the AP-2 family (5,38) suggesting that
DEK may be interacting with other AP-2 family members.
It has recently been suggested that cardiac, neural crest and
neural tube defects in mice lacking Cited2 are produced
because this protein plays a role as AP-2a co-activator (39).
Also, over-expression of some co-activators, such as PC4 and
PARP, partially rescue the malignant phenotype of PA-1 cells
transformed by AP-2a via a mechanism that involve an effect
of these co-activators over other transcription factors (27,40).
Since DEK can partially revert the transformation-prone
phenotype of cells from patients with ataxia-telangiectasia
(41), it is reasonable to think that DEK may rescue this
phenotype due to the action of DEK-dependent transcription
factors, such as AP-2a. In this sense, we can speculate that the
oncogenic activity of the chimera DEK-CAN (26) may be
due to the inhibition of the interaction with AP-2a and
other transcription factors, provoking, as a result, cell
transformation.
It has been demonstrated that DEK is an oncogene
associated with human hepatocellular carcinogenesis (42).
The DEK oncogenic properties and the co-expression of DEK
and AP-2a in several tissues such as spleen, thymus, kidney
and brain (6,26) suggest that DEK could be acting in a
coordinate way with AP-2a in the cell cycle regulation.
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